Journal
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Volume 41, Issue 8, Pages 558-564Publisher
WILEY
DOI: 10.1111/1440-1681.12257
Keywords
angiotensin converting enzyme; coronary heart disease; endothelial nitric oxide synthase; genetic polymorphism; salvianolate injection
Categories
Funding
- Huge Project to Boost Chinese Drug Development [2010ZX09502-003]
- Program for Changjiang Scholars and Innovative Research Team in University [IRT0946]
- National Natural Science Foundation of China [81173129, 81202595]
- Hunan Provincial Natural Science Foundation of China [12JJ7006]
Ask authors/readers for more resources
The purpose of the present study was to clarify the association of eNOS 894G/T and ACE I/D genetic polymorphisms with the risk of coronary heart disease (CHD) and to explore the effects of these polymorphisms on the therapeutic efficacy of salvianolate injection in Chinese CHD patients. In all, 153 CHD patients and 198 healthy controls were enrolled in the study. We collected 5 mL peripheral blood for DNA extraction. Genetic diagnosis of eNOS 894G/T was determined by direct sequencing. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to detect ACE I/D genotypes. We observed significant differences in the frequency distribution of eNOS and ACE polymorphisms between CHD patients and healthy controls (P < 0.05). Binary logistic regression stepwise analysis revealed that the genotypes had an additive and dominant effect on patients' therapeutic responses (P < 0.05). These data suggest that the genetic polymorphisms of ACE I/D and eNOS 894G/T probably play a role in the development of CHD and these genetic polymorphisms may affect the response to salvianolate injection in Chinese CHD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available